FDA greenlights new COVID-19 shots for this fall - Roll Call

The Food and Drug Administration on Monday approved reformulated COVID-19 vaccines from Pfizer Inc. and Moderna Inc., clearing the way for a fall booster campaign amid an increase in infections and a worrying new subvariant.

But the agency deferred an expected emergency authorization for Novavax Inc.’s vaccine, the only traditional protein-based alternative to the mRNA shots from Pfizer and Moderna.

“Novavax is currently responding to the FDA’s requests to facilitate final review, and timing is ultimately at the discretion of the FDA,” the company said in a statement.